Jupiter Topco LLC acquired a new position in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 1,190,973 shares of the company's stock, valued at approximately $22,188,000. Jupiter Topco LLC owned about 0.84% of Trevi Therapeutics as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. AQR Capital Management LLC increased its holdings in shares of Trevi Therapeutics by 20.4% in the 1st quarter. AQR Capital Management LLC now owns 27,720 shares of the company's stock worth $174,000 after purchasing an additional 4,688 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Trevi Therapeutics by 31.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,143 shares of the company's stock worth $278,000 after purchasing an additional 10,445 shares during the last quarter. Millennium Management LLC lifted its holdings in shares of Trevi Therapeutics by 356.3% during the first quarter. Millennium Management LLC now owns 823,249 shares of the company's stock valued at $5,178,000 after purchasing an additional 642,830 shares in the last quarter. Strs Ohio bought a new position in shares of Trevi Therapeutics during the first quarter valued at $52,000. Finally, Creative Planning boosted its position in shares of Trevi Therapeutics by 17.5% during the second quarter. Creative Planning now owns 20,247 shares of the company's stock valued at $111,000 after buying an additional 3,016 shares during the last quarter. 95.76% of the stock is owned by institutional investors.
Trevi Therapeutics Price Performance
TRVI stock opened at $16.79 on Friday. Trevi Therapeutics, Inc. has a 1 year low of $6.93 and a 1 year high of $20.22. The company has a market cap of $2.39 billion, a P/E ratio of -49.38 and a beta of 1.03. The stock's fifty day moving average price is $18.05 and its 200-day moving average price is $14.77.
Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.11) EPS for the quarter, meeting analysts' consensus estimates of ($0.11). As a group, analysts expect that Trevi Therapeutics, Inc. will post -0.48 earnings per share for the current year.
Analyst Ratings Changes
TRVI has been the subject of several research analyst reports. Raymond James Financial reiterated a "strong-buy" rating and issued a $40.00 price objective on shares of Trevi Therapeutics in a report on Friday, August 7th. Oppenheimer raised their price target on shares of Trevi Therapeutics from $24.00 to $25.00 and gave the company an "outperform" rating in a report on Friday, August 7th. BMO Capital Markets assumed coverage on shares of Trevi Therapeutics in a report on Monday, July 20th. They set an "outperform" rating and a $36.00 price target on the stock. B. Riley Financial lifted their price target on shares of Trevi Therapeutics from $21.00 to $31.00 and gave the stock a "buy" rating in a research note on Monday, July 20th. Finally, HC Wainwright boosted their price objective on shares of Trevi Therapeutics from $21.00 to $24.00 and gave the company a "buy" rating in a report on Monday, July 20th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Trevi Therapeutics presently has a consensus rating of "Buy" and an average target price of $27.08.
Check Out Our Latest Report on TRVI
About Trevi Therapeutics
(
Free Report)
Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.
Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.
Featured Stories
Want to see what other hedge funds are holding TRVI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Trevi Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Trevi Therapeutics wasn't on the list.
While Trevi Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
